Atlas company financials

Krystal Biotech, Inc.

Standardized 5-year financial series for Krystal Biotech, Inc., built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0001711279FY2021 → FY2025

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2025

Revenue

$389.1M

Adjusted EBITDA

—

Net result

$204.8M

Net financial debt

—

Latest source: FY2025 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$97.8M

TTM revenue

$365.9M

TTM free cash flow

—

Latest quarter net result

$79.4M

Quarterly coverage: 10 periods · latest quarter FY2025-Q3 · TTM revenue growth 194.8%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
primary · krystal-biotech-inc-fy2021 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2024-02-26 · Retrieved: 2026-04-26T11:49:52.399936+00:00
SEC EDGAR companyfacts
us-gaap:ResearchAndDevelopmentExpense · us gaap companyfacts · primary · krystal-biotech-inc-fy2021 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2022-02-28 · Retrieved: 2026-04-26T11:49:52.399936+00:00
SEC EDGAR companyfacts
us-gaap:SellingGeneralAndAdministrativeExpense · us gaap companyfacts · comparative · krystal-biotech-inc-fy2022 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2025-02-19 · Retrieved: 2026-04-26T11:49:52.399936+00:00
SEC EDGAR companyfacts
us-gaap:ResearchAndDevelopmentExpense · us gaap companyfacts · primary · krystal-biotech-inc-fy2022 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2023-02-27 · Retrieved: 2026-04-26T11:49:52.399936+00:00
SEC EDGAR companyfacts
primary · krystal-biotech-inc-fy2025 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2026-02-17 · Retrieved: 2026-04-26T11:49:52.399936+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2021	0	—	-68M	-70M	-48M	-68M	—	missing accounts receivable · missing adjusted ebitda · missing cost of revenue · missing gross profit · missing inventory · missing net financial debt · missing sg and a
FY2022	0	—	-145M	-140M	-101M	-53M	—	comparative annual fact carried from later 10k · missing adjusted ebitda · missing cost of revenue · missing gross profit · missing net financial debt
FY2023	51M	—	-110M	11M	-89M	-12M	—	missing adjusted ebitda · missing cost of revenue · missing gross profit · missing net financial debt
FY2024	291M	—	66M	89M	123M	-4M	—	missing adjusted ebitda · missing cost of revenue · missing gross profit · missing interest expense · missing net financial debt
FY2025	389M	—	161M	205M	201M	-12M	—	missing adjusted ebitda · missing cost of revenue · missing gross profit · missing interest expense · missing net financial debt

Filing provenance